Carcinoembryonic antigen (CEA) belongs to a family of cell surface glycoproteins. Its level in serum has a significant value for the follow-up and treatment of patients with malignancies. The aim of this study was to correlate the concentration of tumor cytosol CEA (cCEA) with tumor size, patient age and sex, clinical stage, lymph node metastases, and overall survival rate in primary non-small cell lung carcinoma (NSCLC).
Methods and Study Design
The cCEA levels were determined in 76 NSCLC patients by luminescence assay (LIA) and radioimmunoassay (RIA).
Results
A strong correlation between LIA and RIA assay results was found (r = 0.992). No correlation was observed between serum CEA and cCEA levels. Tumors smaller than 3 cm had significantly higher cCEA levels than larger tumors, but when a logistic modeling process was applied this difference was not significant (P = 0.038). Histologically well-differentiated tumors also showed a significantly higher expression of cCEA (P <0.05). In addition, patients without lymph node involvement had higher cCEA levels than patients with tumor-positive lymph nodes (P <0.05). Univariate statistical analysis revealed that the risk of lymph node metastases was 1.8-fold higher in patients with low cCEA levels than in patients with higher levels, taking the median value as cutoff (P = 0.04, Kruskal-Wallis test).
Conclusions
According to the results of our study, patients with overexpression of cCEA may have a better prognosis than those with low cCEA expression. cCEA might therefore be considered a good prognostic parameter as well as a prognostic factor independent of the traditional parameters for lymph node metastases.
GoldP., FreedmanS.O.: Demonstration of tumor-specific antigens in human colonic carcinoma by immunological tolerance and absorption techniques.J Exp Med, 121: 439–462, 1965.
2.
BatesS.E.: Clinical applications of serum tumor markers.Review. Ann Intern Med, 115: 623–638, 1991.
3.
FujimotoS., KitsukawaY.: Further investigations of immunoreactive carcino-embryonic antigen (CEA) in colorectal cancer patients with particular emphasis on the correlation between immunoreactive CEA levels in tissue, feces and blood.Jpn J Surg, 11: 27–32, 1981.
4.
LabergeF., FritscheH.A., UmsawasdiT., CarrD.T., WelchS., MurphyW.K., ChiutenD.F., DhingraH.M., FarhaP., SpitzerG.: Use of carcinoembryonic antigen in small cell lung cancer. Prognostic value and relation to the clinical course.Cancer, 59: 2047–2052, 1987.
5.
SlodkowskaJ., SzturmowiczM., RudzinskiP., GiedronowiczD., SakowiczA., AndrosiukW., Zakrzewska-RowinskaE.: Expression of CEA and trophoblastic cell markers by lung carcinoma in association with histological characteristics and serum marker levels.Eur J Cancer Prev, 7: 51–60, 1998.
6.
VincentR.G., ChuT.M., FergenT.B., OstranderM.: Carcinoembryonic antigen in 228 patients with carcinoma of the lung.Cancer, 36: 2069–2076, 1975.
7.
ImamuraY., YasutakeK., YoshimuraY., OyaM., MatsushitaK., TokisueM., SashikataT.: Contents of tissue CEA and CA 19.9 in colonic polyp and colorectal cancer, and their clinical significance.Gastroenterol Jpn, 25: 186–192, 1990.
8.
ReynosoG., ChuT.M., HolyokeD., CohenE., NemotoT., WangJ.J., ChuangJ., GuinanP., MurphyG.P.: Carcinoembryonic antigen in patients with different cancers.JAMA, 220: 361–365, 1972.
9.
ZamcheckN., MartinE.W.: Factors controlling the circulating CEA levels in pancreatic cancer: some clinical correlations.Cancer, 47: 1620–1630, 1981.
10.
NouwenE.J., PolletD.E., EerdekensM.W., HendrixP.G., BriersT.W., De BroeM.E.: Immunohistochemical localization of placental alkaline phosphatase, carcinoembryonic antigen, and cancer antigen 125 in normal and neoplastic human lung.Cancer Res, 46: 866–876, 1986.
11.
PicardoA.L., DiezM., TorresA., MaestroM., OrtegaD., García-AsenjoJ., MuguersaJ.M., HernandoF., DiezM., BalibreaJ.L.: Quantitative analysis of carcinoembryonic antigen, squamous cell carcinoma antigen, CA 125, and CA 50 cytosolic content in non small cell lung carcinoma.Cancer, 73: 2305–2311, 1994.
12.
SunN.C., EdgingtonT.D., CarpentierC.L., McAffeeW., TerryR., BatemanJ.: Immunohistochemical localization of carcinoembryonic antigen (CEA), CEA-s, and non-specific cross-reacting antigen (NCA) in carcinomas of lung.Cancer, 52: 1632–1641, 1983.
13.
LobinL.H., WittekindC. (Eds): TNM classification of malignant tumours, 5th edition, International Union Against Cancer, pp. 66–69, Wiley-Liss, Inc, New York, 1997.
14.
RainsW.D., ColbyT.V., Carrin, ShimasatoY., BranbillaE.: Histological typing of lung cancer. In: World Health Organisation. International histological classification of tumours, 3rd edition, Springer-Verlag, Heidelberg-Berlin, 1999.
15.
Morales-GutierrezC., VeghI., ColinaF., Gómez-CámaraA., García-CarranzaA., LandaJ.L., BallesterosD., CarreiraP., Enríquez de SalamancaR.: Colorectal cancer survival: possible prognostic value of tissular Carbohydrate antigen CA19.9 determinations.Cancer, 86: 1675–1681, 1999.
16.
BuccheriG.F., ViolanteB., SartorisA.M., FerrignoD., CurcioA., VolaF.: Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma.Cancer, 57: 2389–2396, 1986.
17.
IcardP., RegnardJ.F., EssombaA., PanebiancoV., MagdeleinatP., LevasseurP.: Preoperative carcinoembryonic antigen level as a prognostic indicator in resected primary lung cancer.Ann Thorac Surg, 58: 811–814, 1994.
18.
NismanB., LafairJ., HechingN., LyassO., BarasM., PeretzT., BarakV.: Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in non-small cell lung carcinoma: does the combined use of cytokeratin markers give any additional information?Cancer, 82: 1850–1859, 1998.
19.
GrommS.A., KeevilB.G., ThatcherN., HasletonP.S., SwindellR.S.: The value of tumour markers in lung cancer.Br J Cancer, 58: 797–804, 1988.
20.
SoteloM.T., Vegh PolgáryI., Rodríguez PeraltoJ.L., BallestínC., GutíerrezA., Santos-BrizA., MarrónC., Martín de NicolásJ.L., MillánI., AlvarezE.: Non-small lung cancer (NSCLC): prognostic value of the expression of p53, bcl-2, c-erB2, ADN ploidy and S- phase cell fraction.J Pulmonary Pathol, 1: 19–27, 2000.
21.
SchwartzM.R., RandolphR.L., PankoW.B.: Carcinoembryonic antigen and steroid receptors in cytosol of carcinoma of the breast. Relationship to pathologic and clinical features.Cancer, 55: 2464–2471, 1985.
22.
GrimmT., RiethmullerG., JohnsonJ.P.: Characteristics of carcinoembryonic antigen (CEA) expressed in different cell types: evidence that CEA can function as an adhesion molecule and as a repulsion molecule.Biochem Biophys Res Commun, 204: 1225–1234, 1994.
23.
WagnerH.E., TothC.A., SteeleG.D.Jr., ThomasP.: Metastatic potential of human colon cancer cell lines: relationship to cellular differentiation and carcinoembryonic antigen production.Clin Exp Metastasis, 10: 25–31, 1992.
24.
BenchimolS., FuksA., JothyS., BeaucheminN., ShirotaK., StannersC.P.: Carcinoembryonic antigen, a human tumour marker, functions as an intracellular adhesion molecule.Cell, 57: 327–334, 1989.
25.
JessupJ.M., ThomasP.: Carcinoembryonic antigen: function in metastasis by human colorectal carcinoma.Cancer Metastasis Rev, 8: 263–280, 1989.
26.
HostetterR.B., AugustusL.B., MankariousR., ChiK.F., FanD., ThotC., ThomasP., JessupJ.M.: Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis.J Natl Cancer Inst, 82: 380–385, 1990.
27.
LanduzziL., FabrettiF., RossiI., GriffonoC., De GiovanniC., NicolettiG., NanniP., MinieroR., PalmieriG., SantonoA., LolliniP.L.: Expression of transduced carcino-embryonic antigen gene in human rhabdomyosarcoma inhibits metastasis.Cancer Res, 56: 4503–4508, 1996.
28.
StannersC.P., De MarteL., RojasM., GoldP., FucksA.: Opposite functions for two classes of genes of the human carcinoembryonic antigen family.Tumour Biol, 16: 23–31, 1995.
29.
ScreatonR.A., PennL.Z., StannersC.P.: Carcinoembryonic antigen, a human tumor marker, co-operates with Myc and Bcl-2 in cellular transformation.J Cell Biol, 137: 939–952, 1997.
30.
FoaP., FornierM., MiceliR., SeregniE., SantambrogioL., NosottiM., CataldoJ., CaldieraS., BombardieriE.: Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non small cell lung cancer.Anticancer Res, 19: 3613–3618, 1999.
31.
SalgiaR., HarpoleD., HerndonJ.E.II, PisickE., EliasA., SkarinA.T.: Role of serum tumor markers CA125 and CEA in non-small-cell lung cancer.Anticancer Res, 21: 1241–1246, 2001.
